182 related articles for article (PubMed ID: 36176413)
1. Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases.
Li X; Xia C; Liu M; Liu J; Dong M; Zhao H; Xu S; Wang D; Wei S; Song Z; Chen G; Liu H; Chen J
Front Oncol; 2022; 12():843116. PubMed ID: 36176413
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
Lei J; Zhao J; Gong L; Ni Y; Zhou Y; Tian F; Liu H; Gu Z; Huang L; Lu Q; Wang X; Sun J; Yang E; Wang T; Zhong D; Wang J; Zhao Z; Liu Z; Wang C; Wang X; Lei G; Yan X; Jiang T
JAMA Oncol; 2023 Oct; 9(10):1348-1355. PubMed ID: 37535377
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Hou X; Shi X; Luo J
Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J
J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
Jiang W; Zhou Y; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Guo H; Minervini F; Bongiolatti S; Yang N; Zhang Y; Tao M
Transl Lung Cancer Res; 2022 Apr; 11(4):647-655. PubMed ID: 35529791
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
Front Oncol; 2022; 12():956755. PubMed ID: 36313678
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study.
Zhou H; Lin L; Qin T; Ren W; Tan Y; Yang Q; Xu H; Xie X; Chen Y; Liu S; Li X; Li Z; Hu H; Yu Y; Yao H
J Thorac Dis; 2021 Nov; 13(11):6468-6475. PubMed ID: 34992825
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
Zhou RQ; Luo J; Li LJ; Du M; Wu QC
BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
Wang J; Zhang J; Gao J; Zhao M; Ma Z
Adv Clin Exp Med; 2023 Sep; ():. PubMed ID: 37676100
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
[TBL] [Abstract][Full Text] [Related]
17. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.
Wu Z; Zheng Q; Chen H; Xiang J; Hu H; Li H; Pan Y; Peng Y; Yao X; Liu P; Sun Y; Li B; Zhang Y
J Thorac Dis; 2021 Jun; 13(6):3518-3528. PubMed ID: 34277047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
